-
-
-
-
-
-
-
Novo Nordisk (NVO) Misses Q1 EPS by 33c
-
-
-
-
-
-
-
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
-
-
-
-
-
-
-
Mangoceuticals clarifies GLP-1 weight-management program launch
-
-
-
-
-
-
-
Novo Nordisk (NVO) PT Raised to $55 at BMO Capital
-
-
-
-
-
-
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
-
-
-
-
-
-
BofA lowers rating of Novo Nordisk after Wegovy-maker issues profit warning
-
-
-
-
-
-
-
Novo Nordisk earnings preview: Q1 miss, guidance cut in focus as obesity drug demand cools
-
1,227,473 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

